Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Dyax grants Kadmon exclusive license for anticancer candidate

Sep. 21, 2012

The Leukemia & Lymphoma Society to support BET inhibitor program

Sep. 21, 2012

Cancer Therapeutics CRC synthesizes novel FADK inhibitors

Sep. 21, 2012

Afatinib demonstrates significant improvements in PFS in the LUX-lung 3 phase III trial

Sep. 21, 2012

Phase II study begins of Zevalin in lymphoma

Sep. 20, 2012

Baxter and Onconova enter into European licensing agreement for rigosertib

Sep. 20, 2012

IRM discloses new Trk inhibitors

Sep. 20, 2012

Phase III trial begins for theragnostic drug in patients with progressive midgut carcinoid

Sep. 20, 2012

International partnership initiates phase II study of PI3K inhibitor in breast cancer

Sep. 19, 2012

Chugai files for approval of Avastin for additional indication in Japan

Sep. 19, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...